Metabolomic Profiling Distinction of Human Nonalcoholic Fatty Liver Disease Progression from a Common Rat Model

被引:42
|
作者
Han, JianHua [1 ,2 ]
Dzierlenga, Anika L. [1 ]
Lu, Zhengqiang [3 ]
Billheimer, Dean D. [3 ]
Torabzadeh, Elmira [3 ]
Lake, April D. [1 ]
Li, Hui [1 ]
Novak, Petr [4 ]
Shipkova, Petia [5 ]
Aranibar, Nelly [5 ]
Robertson, Donald [5 ]
Reily, Michael D. [5 ]
Lehman-McKeeman, Lois D. [5 ]
Cherrington, Nathan J. [1 ]
机构
[1] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China
[3] Univ Arizona, Arizona Stat Consulting Lab, Tucson, AZ USA
[4] Biol Ctr CAS, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic
[5] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Princeton, NJ USA
基金
美国国家卫生研究院;
关键词
BILE-ACIDS; TRANSPORTER EXPRESSION; CHOLINE; STEATOSIS; PATHOLOGY; TOXICITY;
D O I
10.1002/oby.21855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Characteristic pathological changes define the progression of steatosis to nonalcoholic steatohepatitis (NASH) and are correlated to metabolic pathways. A common rodent model of NASH is the methionine and choline deficient (MCD) diet. The objective of this study was to perform full metabolomic analyses on liver samples to determine which pathways are altered most pronouncedly in this condition in humans, and to compare these changes to rodent models of nonalcoholic fatty liver disease (NAFLD). Methods: A principal component analysis for all 91 metabolites measured indicated that metabolome perturbation is greater and less varied for humans than for rodents. Results: Metabolome changes in human and rat NAFLD were greatest for the amino acid and bile acid metabolite families (e.g., asparagine, citrulline, gamma-aminobutyric acid, lysine); although, in many cases, the trends were reversed when compared between species (cholic acid, betaine). Conclusions: Overall, these results indicate that metabolites of specific pathways may be useful biomarkers for NASH progression, although these markers may not correspond to rodent NASH models. The MCD model may be useful when studying certain end points of NASH; however, the metabolomics results indicate important differences between humans and rodents in the biochemical pathogenesis of the disease.
引用
收藏
页码:1069 / 1076
页数:8
相关论文
共 50 条
  • [41] Molecular pathways of nonalcoholic fatty liver disease development and progression
    Bessone, Fernando
    Valeria Razori, Maria
    Roma, Marcelo G.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (01) : 99 - 128
  • [42] Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
    Marengo, Andrea
    Jouness, Ramy Ibrahim Kamal
    Bugianesi, Elisabetta
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 313 - +
  • [43] The Chromatin Accessibility Landscape of Nonalcoholic Fatty Liver Disease Progression
    Kang, Byeonggeun
    Kang, Byunghee
    Roh, Tae-Young
    Seong, Rho Hyun
    Kim, Won
    MOLECULES AND CELLS, 2022, 45 (05) : 343 - 352
  • [44] Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
    Almeda-Valdes, Paloma
    Aguilar-Olivos, Nancy
    Uribe, Misael
    Mendez-Sanchez, Nahum
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) : 148 - 158
  • [45] Fatty acid metabolites as biomarkers for nonalcoholic fatty liver disease (NAFLD): A lipidomic and metabolomic approach
    Hou, S.
    Li, Z.
    Zhou, Y. H.
    Meng, T.
    Zhu, M. G.
    Yin, H. Y.
    FREE RADICAL BIOLOGY AND MEDICINE, 2012, 53 : S244 - S245
  • [46] In Vitro Nonalcoholic Fatty Liver Disease Model Elucidating the Effect of Immune Environment on Disease Progression and Alleviation
    Kim, Inhye
    Kyun, Mi-lang
    Jung, Hyewon
    Kwon, Ji-In
    Kim, Jeongha
    Kim, Ju-Kang
    Lee, Yu Bin
    Kwon, Young-In
    Moon, Kyoung-Sik
    ACS OMEGA, 2024, 9 (23): : 25094 - 25105
  • [47] Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model
    Gorden, D. Lee
    Ivanova, Pavlina T.
    Myers, David S.
    McIntyre, J. Oliver
    VanSaun, Michael N.
    Wright, J. Kelly
    Matrisian, Lynn M.
    Brown, H. Alex
    PLOS ONE, 2011, 6 (08):
  • [48] Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease
    Laursen, Tea Lund
    Mellemkjaer, Anders
    Moller, Holger Jon
    Gronbaek, Henning
    Kazankov, Konstantin
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (08) : 697 - 705
  • [49] Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
    Pierantonelli, Irene
    Svegliati-Baroni, Gianluca
    TRANSPLANTATION, 2019, 103 (01) : e1 - e13
  • [50] Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON)
    Kohli, Rohit
    Sunduram, Shikha
    Mouzaki, Marialena
    Ali, Sabina
    Sathya, Pushpa
    Abrams, Stephanie
    Xanthakos, Stavra A.
    Vos, Miriam
    Schwimmer, Jeffrey B.
    JOURNAL OF PEDIATRICS, 2016, 172 : 9 - 13